Table of Contents
ISRN Infectious Diseases
Volume 2013 (2013), Article ID 387925, 11 pages
http://dx.doi.org/10.5402/2013/387925
Review Article

Transmissible Spongiform Encephalopathies Affecting Humans

Department of Pharmacology & Toxicology, College of Veterinary Science & Animal Husbandry, Sardarkrushinagar Dantiwada Agricultural University, Sardarkrushinagar 385506, Gujarat, India

Received 2 April 2012; Accepted 5 May 2012

Academic Editors: A. Carvalho, K. Peoc'H, and T. A. Rupprecht

Copyright © 2013 Dudhatra G. B. et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Palmer, A. J. Dryden, J. T. Hughes, and J. Collinge, “Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease,” Nature, vol. 352, no. 6333, pp. 340–342, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Tahiri-Alaoui, A. C. Gill, P. Disterer, and W. James, “Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant. Implications for disease susceptibility to Creutzfeldt-Jakob disease,” Journal of Biological Chemistry, vol. 279, no. 30, pp. 31390–31397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. R. C. Holman, A. S. Khan, E. D. Belay, and L. B. Schonberger, “Creutzfeldt-Jakob disease in the United States, 1979–1994: using national mortality data to assess the possible occurrence of variant cases,” Emerging Infectious Diseases, vol. 2, no. 4, pp. 333–337, 1996. View at Google Scholar · View at Scopus
  4. P. Brown, F. Cathala, P. Castaigne, and D. C. Gajdusek, “Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases,” Annals of Neurology, vol. 20, no. 5, pp. 597–602, 1986. View at Google Scholar · View at Scopus
  5. R. K. Obi and F. C. Nwanebu, “Prions and Prion diseases,” African Journal of Clinical and Experimental Microbiology, vol. 9, no. 1, pp. 38–52, 2008. View at Google Scholar
  6. J. Solassol, M. Pastore, C. Crozet, V. Perrier, and S. Lehmann, “A novel copper-hydrogen peroxide formulation for prion decontamination,” Journal of Infectious Diseases, vol. 194, no. 6, pp. 865–869, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. H. A. Kretzschmar, “Human prion diseases (spongiform encephalopathies),” Archives of Virology, vol. 7, pp. 261–293, 1993. View at Google Scholar · View at Scopus
  8. P. Brown, “EEG findings in Creutzfeldt-Jakob disease,” Journal of the American Medical Association, vol. 269, no. 24, p. 3168, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Hsich, K. Kenney, C. J. Gibbs, K. H. Lee, and M. G. Harrington, “The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies,” New England Journal of Medicine, vol. 335, no. 13, pp. 924–930, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. H. A. Kretzschmar, J. W. Ironside, S. J. DeArmond, and J. Tateishi, “Diagnostic criteria for sporadic Creutzfeldt-Jakob disease,” Archives of Neurology, vol. 53, no. 9, pp. 913–920, 1996. View at Google Scholar · View at Scopus
  11. S. J. DeArmond and S. B. Prusiner, “Etiology and pathogenesis of prion diseases,” American Journal of Pathology, vol. 146, no. 4, pp. 785–811, 1995. View at Google Scholar · View at Scopus
  12. M. Caramelli, G. Ru, P. Acutis, and G. Forloni, “Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances,” CNS Drugs, vol. 20, no. 1, pp. 15–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Collins, P. Sanchez-Juan, C. L. Masters et al., “Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease,” Brain, vol. 129, no. 9, pp. 2278–2287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Budka, “Neuropathology of prion diseases,” British Medical Bulletin, vol. 66, pp. 121–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. D. F. Wadsworth, S. Joiner, J. M. Linehan et al., “Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein,” Brain, vol. 129, no. 6, pp. 1557–1569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Collinge, “Human prion diseases and bovine spongiform encephalopathy (BSE),” Human Molecular Genetics, vol. 6, no. 10, pp. 1699–1705, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Mead, “Prion disease genetics,” European Journal of Human Genetics, vol. 14, no. 3, pp. 273–281, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Mead, S. P. Mahal, J. Beck et al., “Sporadic—But not variant—Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1,” American Journal of Human Genetics, vol. 69, no. 6, pp. 1225–1235, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Vollmert, O. Windl, W. Xiang et al., “Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study,” Journal of medical genetics, vol. 43, no. 10, article e 53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Budka, A. Aguzzi, P. Brown et al., “Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases),” Brain Pathology, vol. 5, no. 4, pp. 459–466, 1995. View at Google Scholar · View at Scopus
  21. I. Zerr, M. Bodemer, O. Gefeller et al., “Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease,” Annals of Neurology, vol. 43, no. 1, pp. 32–40, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. C. L. Masters, D. C. Gajdusek, and C. J. Gibbs, “Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Straussler syndrome. With an analysis of the various forms of amyloid plaque deposition in the virus-induced spongiform encephalopathies,” Brain, vol. 104, no. 3, pp. 559–588, 1981. View at Google Scholar · View at Scopus
  23. P. Brown, M. Preece, J. P. Brandel et al., “Iatrogenic Creutzfeldt-Jakob disease at the millennium,” Neurology, vol. 55, no. 8, pp. 1075–1081, 2000. View at Google Scholar · View at Scopus
  24. C. A. Heath, R. A. Barker, T. F. G. Esmonde et al., “Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 7, pp. 880–882, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. D. F. Wadsworth and J. Collinge, “Update on human prion disease,” Biochimica et Biophysica Acta, vol. 1772, no. 6, pp. 598–609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Duffy, J. Wolf, G. Collins, A. G. DeVoe, B. Streeten, and D. Cowen, “Letter: possible person-to-person transmission of Creutzfeldt-Jakob disease,” New England Journal of Medicine, vol. 290, no. 12, pp. 692–693, 1974. View at Google Scholar · View at Scopus
  27. C. Masters, J. O. Harris, and D. C. Gajdusek, “Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering,” Annals of Neurology, vol. 5, no. 2, pp. 177–188, 1979. View at Google Scholar · View at Scopus
  28. P. Brown, D. C. Gajdusek, C. J. Gibbs, and D. M. Asher, “Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy,” New England Journal of Medicine, vol. 313, no. 12, pp. 728–731, 1985. View at Google Scholar · View at Scopus
  29. M. N. Ricketts, N. R. Cashman, E. E. Stratton, and S. ElSaadany, “Is Creutzfeldt-Jakob disease transmitted in blood?” Emerging Infectious Diseases, vol. 3, no. 2, pp. 155–163, 1997. View at Google Scholar · View at Scopus
  30. A. Créange, F. Gray, P. Cesaro et al., “Creutzfeldt-Jakob disease after liver transplantation,” Annals of Neurology, vol. 38, no. 2, pp. 269–272, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. E. E. Manuelidis, J. H. Kim, J. R. Mericangas, and L. Manuelidis, “Transmission to animals of Creutzfeldt-Jakob disease from human blood,” Lancet, vol. 2, no. 8460, pp. 896–897, 1985. View at Google Scholar · View at Scopus
  32. H. J. Tschampa, P. Mürtz, S. Flacke, S. Paus, H. H. Schild, and H. Urbach, “Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study,” American Journal of Neuroradiology, vol. 24, no. 5, pp. 908–915, 2003. View at Google Scholar · View at Scopus
  33. P. Sanchez-Juan, A. Green, A. Ladogana et al., “CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease,” Neurology, vol. 67, no. 4, pp. 637–643, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. M. H. Tattum, S. Jones, S. Pal, A. Khalili-Shirazi, J. Collinge, and G. S. Jackson, “A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K,” Transfusion, vol. 50, no. 12, pp. 2619–2627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. E. D. Belay and L. B. Schonberger, “Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy,” Clinics in Laboratory Medicine, vol. 22, no. 4, pp. 849–862, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Pfeifer, S. Eigenbrod, S. Al-Khadra et al., “Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice,” Journal of Clinical Investigation, vol. 116, no. 12, pp. 3204–3210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. E. P. Richardson and C. L. Masters, “The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of PrPCJD in the nervous system,” Brain Pathology, vol. 5, no. 1, pp. 33–41, 1995. View at Google Scholar · View at Scopus
  38. G. De Michele, M. Pocchiari, R. Petraroli et al., “Variable phenotype in a P102L Gerstmann-Sträussler-Scheinker Italian family,” Canadian Journal of Neurological Sciences, vol. 30, no. 3, pp. 233–236, 2003. View at Google Scholar · View at Scopus
  39. D. C. Gajdusek, “Infectious amyloides: subacute spongiform encephalopathies as transmissible cerebral amyloidoses,” in Fields Virology, B. N. Fields, D. M. Knipe, and P. M. Howley, Eds., pp. 2851–2900, 3rd edition, 1996. View at Google Scholar
  40. H. Arata, H. Takashima, R. Hirano et al., “Early clinical signs and imaging findings in Gerstmann-Sträussler- Scheinker syndrome (Pro102Leu),” Neurology, vol. 66, no. 11, pp. 1672–1678, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Ghetti, P. Piccardo, B. Frangione et al., “Prion protein amyloidosis,” Brain Pathology, vol. 6, no. 2, pp. 127–145, 1996. View at Google Scholar · View at Scopus
  42. H. A. Kretzschmar, G. Honold, F. Seitelberger et al., “Prion protein mutation in family first reported by Gerstmann, Straussler, and Scheinker,” Lancet, vol. 337, no. 8750, p. 1160, 1991. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Collins, C. A. McLean, and C. L. Masters, “Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies,” Journal of Clinical Neuroscience, vol. 8, no. 5, pp. 387–397, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Lugaresi, R. Medori, and P. Montagna, “Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei,” New England Journal of Medicine, vol. 315, no. 16, pp. 997–1003, 1986. View at Google Scholar · View at Scopus
  45. R. Medori, H. J. Tritschler, A. LeBlanc et al., “Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene,” New England Journal of Medicine, vol. 326, no. 7, pp. 444–449, 1992. View at Google Scholar · View at Scopus
  46. I. Zerr, A. Giese, O. Windl et al., “Phenotypic variability in fatal familial insomnia (D178N-129M) genotype,” Neurology, vol. 51, no. 5, pp. 1398–1405, 1998. View at Google Scholar · View at Scopus
  47. P. Parchi, S. Capellari, S. Chin et al., “A subtype of sporadic prion disease mimicking fatal familial insomnia,” Neurology, vol. 52, no. 9, pp. 1757–1763, 1999. View at Google Scholar · View at Scopus
  48. J. Chapman, A. Arlazoroff, L. G. Goldfarb et al., “Fatal insomnia in a case of familial Creutzfeldt-Jakob disease with the codon 200Lys mutation,” Neurology, vol. 46, no. 3, pp. 758–761, 1996. View at Google Scholar · View at Scopus
  49. R. B. Petersen, M. Tabaton, L. Berg et al., “Analysis of the prion protein gene in thalamic dementia,” Neurology, vol. 42, no. 10, pp. 1859–1863, 1992. View at Google Scholar · View at Scopus
  50. L. G. Goldfarb, M. Haltia, P. Brown et al., “New mutation in scrapie amyloid precursor gene (at codon 178) in finnish Creutzfield-Jakob kindred,” Lancet, vol. 337, no. 8738, p. 425, 1991. View at Google Scholar · View at Scopus
  51. L. G. Goldfarb, R. B. Petersen, M. Tabaton et al., “Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism,” Science, vol. 258, no. 5083, pp. 806–808, 1992. View at Google Scholar · View at Scopus
  52. R. B. Petersen, P. Parchi, S. L. Richardson, C. B. Urig, and P. Gambetti, “Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein,” Journal of Biological Chemistry, vol. 271, no. 21, pp. 12661–12668, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Monari, S. G. Chen, P. Brown et al., “Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 7, pp. 2839–2842, 1994. View at Google Scholar · View at Scopus
  54. P. Gambetti, P. Parchi, R. B. Petersen, S. G. Chen, and E. Lugaresi, “Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features,” Brain Pathology, vol. 5, no. 1, pp. 43–51, 1995. View at Google Scholar · View at Scopus
  55. Y. Taniwaki, H. Hara, K. Doh-Ura et al., “Familial Creutzfeldt-Jakob disease with D178N-129M mutation of PRNP presenting as cerebellar ataxia without insomnia,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 3, p. 388, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Almer, J. A. Hainfellner, T. Brücke et al., “Fatal familial insomnia: a new Austrian family,” Brain, vol. 122, no. 1, pp. 5–16, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Lugaresi, I. Tobler, P. Gambetti, and P. Montagna, “The pathophysiology of fatal familial insomnia,” Brain Pathology, vol. 8, no. 3, pp. 521–526, 1998. View at Google Scholar · View at Scopus
  58. P. Silburn, L. Cervenáková, P. Varghese, A. Tannenberg, P. Brown, and R. Boyle, “Fatal familial insomnia: a seventh family,” Neurology, vol. 47, no. 5, pp. 1326–1328, 1996. View at Google Scholar · View at Scopus
  59. C. A. McLean, E. Storey, R. J. M. Gardner, A. E. G. Tannenberg, L. Cervenáková, and P. Brown, “The D178N (cis-129M) 'fatal familial insomnia' mutation associated with diverse clinicopathologic phenotypes in an Australian kindred,” Neurology, vol. 49, no. 2, pp. 552–558, 1997. View at Google Scholar · View at Scopus
  60. C. Tabernero, J. Figols, N. Cuadrado et al., “Fatal familial insomnia: clinical, neuropathological, and genetic description of a Spanish family,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 6, pp. 774–777, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Manetto, R. Medori, P. Cortelli et al., “Fatal familial insomnia: clinical and pathologic study of five new cases,” Neurology, vol. 42, no. 2, pp. 312–319, 1992. View at Google Scholar · View at Scopus
  62. J. Schenkein and P. Montagna, “Self-management of fatal familial insomnia. Part 2: case report,” Medscape General Medicine, vol. 8, no. 3, article 66, 2006. View at Google Scholar · View at Scopus
  63. W. S. Jackson, A. W. Borkowski, H. Faas et al., “Spontaneous generation of prion infectivity in fatal familial insomnia Knockin Mice,” Neuron, vol. 63, no. 4, pp. 438–450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Mead, M. P. H. Stumpf, J. Whitfield et al., “Balancing selection at the prion protein gene consistent with prehistoric Kurulike epidemics,” Science, vol. 300, no. 5619, pp. 640–643, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Alpers, “Epidemiology and clinical aspects of Kuru,” in Prions: Novel Infectious Pathogens Causing Scrapie and Creutzfeldt-Jakob Disease, S. B. Prusiner and M. P. McKinley, Eds., pp. 451–465, Academic Press, San Diego, Calif, USA, 1987. View at Google Scholar
  66. S. Lindenbaum, Kuru Sorcery: Disease and Danger in the New Guinea Highlands, Mayfield, Palo Alto, Calif, USA, 1979.
  67. J. Collinge, J. Whitfield, E. McKintosh et al., “Kuru in the 21st century-an acquired human prion disease with very long incubation periods,” Lancet, vol. 367, no. 9528, pp. 2068–2074, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. H. S. Lee, P. Brown, L. Cervenáková et al., “Increased susceptibility to kuru of carriers of the PRNP 129 methionine/methionine genotype,” Journal of Infectious Diseases, vol. 183, no. 2, pp. 192–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Mallucci and J. Collinge, “Rational targeting for prion therapeutics,” Nature Reviews Neuroscience, vol. 6, no. 1, pp. 23–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. C. R. Trevitt and J. Collinge, “A systematic review of prion therapeutics in experimental models,” Brain, vol. 129, no. 9, pp. 2241–2265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Aguzzi, M. Glatzel, F. Montrasio, M. Prinz, and F. L. Heppner, “Interventional strategies against prion diseases,” Nature Reviews Neuroscience, vol. 2, no. 10, pp. 745–749, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. G. R. Mallucci, M. D. White, M. Farmer et al., “Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice,” Neuron, vol. 53, no. 3, pp. 325–335, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. A. R. White, P. Enever, M. Tayebi et al., “Monoclonal antibodies inhibit prion replication and delay the development of prion disease,” Nature, vol. 422, no. 6927, pp. 80–83, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Solforosi, J. R. Criado, D. B. McGavern et al., “Cross-linking cellular prion protein triggers neuronal apoptosis in vivo,” Science, vol. 303, no. 5663, pp. 1514–1516, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Tilly, J. Chapuis, D. Vilette, H. Laude, and J. L. Vilotte, “Efficient and specific down-regulation of prion protein expression by RNAi,” Biochemical and Biophysical Research Communications, vol. 305, no. 3, pp. 548–551, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. M. D. White, M. Farmer, I. Mirabile, S. Brandner, J. Collinge, and G. R. Mallucci, “Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10238–10243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Paramithiotis, M. Pinard, T. Lawton et al., “A prion protein epitope selective for the pathologically misfolded conformation,” Nature Medicine, vol. 9, no. 7, pp. 893–899, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. D. R. Jones, W. A. Taylor, C. Bate, M. David, and M. Tayebi, “A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines,” PloS One, vol. 5, no. 3, article e9804, 2010. View at Google Scholar · View at Scopus
  79. C. J. Johnson, J. P. Bennett, S. M. Biro et al., “Degradation of the disease-associated prion protein by a serine protease from lichens,” PLoS One, vol. 6, no. 5, Article ID e19836, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Yam, “Natural born prion killers: lichens degrade "mad cow" related brain pathogen,” Scientific American, 2011, http://www.scientificamerican.com/blog/post.cfm?id=natural-born-prion-killers-lichens-2011-05-19.
  81. R. Rubenstein, B. Chang, P. Gray et al., “A novel method for preclinical detection of PrPSc in blood,” Journal of General Virology, vol. 91, no. 7, pp. 1883–1892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. “SOFIA: an assay platform for ultrasensitive detection of PrPSc in brain and blood,” Suny Downstate Medical Center, 2011, http://www.bionosis.com/news/Bionosis%20PrioNet%20Poster.pdf.